BR0109747A - Uso de 5-(2-pirazinil)-4-metil-1-2-ditiol-3-tiona (oltipraz) como um medicamento, composição farmacêutica para a prevenção e tratamento da progressão da fibrose hepática, uso de 5-(2-pirazinil)-4-metil-1, 2-ditiol-3-tiona e método para a prevenção e tratamento da progressão da fibrose e da cirrose hepática - Google Patents

Uso de 5-(2-pirazinil)-4-metil-1-2-ditiol-3-tiona (oltipraz) como um medicamento, composição farmacêutica para a prevenção e tratamento da progressão da fibrose hepática, uso de 5-(2-pirazinil)-4-metil-1, 2-ditiol-3-tiona e método para a prevenção e tratamento da progressão da fibrose e da cirrose hepática

Info

Publication number
BR0109747A
BR0109747A BR0109747-4A BR0109747A BR0109747A BR 0109747 A BR0109747 A BR 0109747A BR 0109747 A BR0109747 A BR 0109747A BR 0109747 A BR0109747 A BR 0109747A
Authority
BR
Brazil
Prior art keywords
prevention
treatment
methyl
oltipraz
thione
Prior art date
Application number
BR0109747-4A
Other languages
English (en)
Inventor
Sang-Geon Kim
Keon-Wook Kang
Original Assignee
Sang-Geon Kim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sang-Geon Kim filed Critical Sang-Geon Kim
Publication of BR0109747A publication Critical patent/BR0109747A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"USO DE 5-(2-PIRAZINIL)-4-METIL-1, 2-DITIOL-3-TIONA(OLTIPRAZ) COMO UM MEDICAMENTO, COMPOSIçãO FARMACêUTICA PARA A PREVENçãO E TRATAMENTO DA PROGRESSãO DA FIBROSE HEPáTICA, USO DE 5-(2-PIRAZINIL)-4-METIL-1, 2-DITIOL-3-TIONA E MéTODO PARA A PREVENçãO E TRATAMENTO DA PROGRESSãO DA FIBROSE E DA CIRROSE HEPáTICA". A presente invenção proporciona um uso profilático e terapêutico de 5-(2-pirazinil)-4-metil-1,2-ditiol-3-tiona (oltipraz) como um agente antifibrótico e anticirrótico no fígado e uma composição farmacêutica contento oltipraz para o tratamento e a prevenção da fibrose e da cirrose hepática. O oltipraz da invenção pode ser usado como um medicamento opcionalmente com outras drogas para o tratamento e a prevenção da fibrose e da cirrose hepática e apresenta um efeito inibitório da fibrose hepática em dosagem relativamente baixa. Formulações usando uma dose ótima de oltipraz, a qual é provida pela invenção, possuem um efeito surpreendentemente bom sobre o tratamento e a prevenção da fibrose e da cirrose hepática e são drogas seguras que possuem baixa toxicidade sobre o organismo humano.
BR0109747-4A 2000-04-07 2001-03-02 Uso de 5-(2-pirazinil)-4-metil-1-2-ditiol-3-tiona (oltipraz) como um medicamento, composição farmacêutica para a prevenção e tratamento da progressão da fibrose hepática, uso de 5-(2-pirazinil)-4-metil-1, 2-ditiol-3-tiona e método para a prevenção e tratamento da progressão da fibrose e da cirrose hepática BR0109747A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20000018134 2000-04-07
PCT/KR2001/000319 WO2001076604A1 (en) 2000-04-07 2001-03-02 Prophylactic and therapeutic use of oltipraz as an antifibrotic and anticirrhotic agent in the liver and pharmaceutical composition containing oltipraz

Publications (1)

Publication Number Publication Date
BR0109747A true BR0109747A (pt) 2003-02-04

Family

ID=19662428

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0109747-4A BR0109747A (pt) 2000-04-07 2001-03-02 Uso de 5-(2-pirazinil)-4-metil-1-2-ditiol-3-tiona (oltipraz) como um medicamento, composição farmacêutica para a prevenção e tratamento da progressão da fibrose hepática, uso de 5-(2-pirazinil)-4-metil-1, 2-ditiol-3-tiona e método para a prevenção e tratamento da progressão da fibrose e da cirrose hepática

Country Status (16)

Country Link
US (1) US20030191137A1 (pt)
EP (1) EP1292309A4 (pt)
JP (1) JP2003530353A (pt)
KR (1) KR100404303B1 (pt)
CN (1) CN1192775C (pt)
AU (1) AU780161B2 (pt)
BR (1) BR0109747A (pt)
CA (1) CA2404915A1 (pt)
HU (1) HUP0300221A3 (pt)
MX (1) MXPA02009695A (pt)
NO (1) NO20024724L (pt)
NZ (1) NZ521710A (pt)
PL (1) PL362965A1 (pt)
RU (1) RU2258509C2 (pt)
WO (1) WO2001076604A1 (pt)
ZA (1) ZA200207867B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078045B2 (en) 2000-03-02 2006-07-18 Sang-Geon Kim Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis
KR20030067935A (ko) * 2002-02-09 2003-08-19 김상건 올티프라즈를 포함하는 간경화(간경변증) 치료를 위한 간 조직 재생용 제약 조성물
KR100491318B1 (ko) * 2002-11-26 2005-05-24 씨제이 주식회사 올티프라즈(Ｏｌｔｉｐｒａｚ) 제조방법
KR100476069B1 (ko) * 2003-02-12 2005-03-10 주식회사 태평양 １，２－디티올티온 유도체를 함유하는 발모촉진용 또는탈모방지용 조성물
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
KR100604261B1 (ko) * 2004-10-11 2006-07-28 재단법인서울대학교산학협력재단 신규4,5,6,7-테트라히드로-[1,2]디티올로[4,3-ｃ]피리딘-3-티온계 화합물
KR100590818B1 (ko) 2004-10-11 2006-06-19 재단법인서울대학교산학협력재단 소분자 유기화합물의 직접적 ｐ90 리보솜 Ｓ6 키나제 1(ＲＳＫ1)의 활성증진에 의한 당뇨병, 비만 및대사증후군의 예방 및 치료용도
KR20060031956A (ko) * 2004-10-11 2006-04-14 재단법인서울대학교산학협력재단 ｐ90 리보솜 Ｓ6 키나제 1 (ＲＳＫ1)의 직접적인 키나제활성증진을 통한 간섬유화와 간경변증 예방 및 치료용약학조성물
US8076311B2 (en) * 2006-05-11 2011-12-13 Prendergast Patrick T Compositions and methods for modulating the immune system
KR101057485B1 (ko) * 2008-08-04 2011-08-17 서울대학교산학협력단 1,2-디티올티온 유도체를 함유하는 엘엑스알-알파 과다발현으로 인한 질병의 예방 및 치료용 약학 조성물
CA2919316C (en) * 2013-07-30 2021-08-10 Kyoto Prefectural Public University Corporation Corneal endothelial ecm therapeutic medicaments
RU2712967C2 (ru) 2013-10-31 2020-02-03 Киото Прифекчурал Паблик Юниверсити Корпорэйшн Терапевтическое средство против заболеваний, связанных с гибелью клеток эндотелия роговицы, обусловленной состоянием эндоплазматического ретикулума
US20160376259A1 (en) 2015-06-25 2016-12-29 St Ip Holding Ag Methods for Preparing Oltipraz
US11364239B2 (en) 2020-04-29 2022-06-21 Cfd Research Corporation Compositions and methods for mitigating aflatoxin B1-induced liver injury
CN112546216B (zh) * 2020-11-20 2022-10-28 西湖大学 小分子化合物奥替普拉在制备增强体液免疫应答的药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794873A (fr) * 1972-02-02 1973-08-01 Rhone Poulenc Sa Nouvelles sulfones a enchainement dimethyl-1,6 hexadien-1,5 ylene
DE2505869C3 (de) * 1975-02-12 1978-05-18 Basf Ag, 6700 Ludwigshafen Verfahren zur Herstellung von symmetrischen Carotinoiden
JPS54160740A (en) * 1978-06-09 1979-12-19 Takeda Chem Ind Ltd Anti-fibrotic agent
US4883887A (en) * 1987-07-09 1989-11-28 Hoffmann-La Roche Inc. Sulfone polyene intermediates
US6517824B1 (en) * 1990-05-14 2003-02-11 University Of Medicine & Denistry Of New Jersey Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
US5637315A (en) * 1993-01-04 1997-06-10 Thomas Jefferson University Treatment of disease states induced by oxidative stress
KR0138005B1 (ko) * 1993-10-21 1998-05-15 김낙두 신규의 화학적 보호제(chemopreventive agent)및 그의 제조방법
CA2113229C (en) * 1994-01-11 1999-04-20 Mark Pines Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
EP0827742A1 (en) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
US6350467B1 (en) * 1996-12-31 2002-02-26 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
US6294350B1 (en) * 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
KR100261139B1 (ko) * 1998-01-16 2000-08-01 황준수 신규한 알릴티오피리다진 유도체 및 그의 제조방법
US6242478B1 (en) * 1999-12-10 2001-06-05 Wake Forest University Five member ring sulfenate esters and thiosulfinate esters

Also Published As

Publication number Publication date
RU2002129873A (ru) 2004-03-27
CN1420772A (zh) 2003-05-28
AU780161B2 (en) 2005-03-03
KR100404303B1 (ko) 2003-11-03
CN1192775C (zh) 2005-03-16
US20030191137A1 (en) 2003-10-09
JP2003530353A (ja) 2003-10-14
NZ521710A (en) 2004-06-25
RU2258509C2 (ru) 2005-08-20
KR20010091012A (ko) 2001-10-22
NO20024724L (no) 2002-11-29
EP1292309A4 (en) 2004-08-11
AU3776701A (en) 2001-10-23
HUP0300221A3 (en) 2003-09-29
MXPA02009695A (es) 2003-03-27
ZA200207867B (en) 2003-08-01
PL362965A1 (en) 2004-11-02
CA2404915A1 (en) 2001-10-18
NO20024724D0 (no) 2002-10-02
EP1292309A1 (en) 2003-03-19
WO2001076604A1 (en) 2001-10-18
HUP0300221A2 (hu) 2003-07-28

Similar Documents

Publication Publication Date Title
BR0109747A (pt) Uso de 5-(2-pirazinil)-4-metil-1-2-ditiol-3-tiona (oltipraz) como um medicamento, composição farmacêutica para a prevenção e tratamento da progressão da fibrose hepática, uso de 5-(2-pirazinil)-4-metil-1, 2-ditiol-3-tiona e método para a prevenção e tratamento da progressão da fibrose e da cirrose hepática
WO2007022090A3 (en) Topical delivery with a carrier fluid
AR020001A1 (es) COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO
ATE309798T1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
BR0307540A (pt) Preparação farmacêutica em forma de filme ou em forma de lâmina para administrar substâncias ativas, uso da preparação farmacêutica e processo para a administração oral de substância(s) farmaceuticamente ativa(s) dotadas de sabor amargo
CR8352A (es) Formulaciones farmaceuticas, procedimientos y pautas de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
CO5170471A1 (es) Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
BR0109336A (pt) Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico
GB0814302D0 (en) Compounds and methods
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
WO2005055921A3 (en) Compositions for treatment of ear disorders and methods of use thereof
WO2005044226A3 (en) Lipid formulations for spontaneous drug encapsulation
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
DE50203456D1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
DE60211139D1 (de) Feste arzneizusammensetzung enthaltend 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide und pvp
DE69718734D1 (de) Bicyclische aromatische verbindungen
MX9501849A (es) Nuevos compuestos biciclicos-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos.
BRPI0406858A (pt) Liberação controlada de agentes altamente solúveis
DE60115631D1 (de) Halbfester verabreichungsträger und arzneimittel
KR970032872A (ko) 아세틸살리실산을 함유하는 피부 손상 처치용 약물
UY27539A1 (es) Formulación farmacéutica
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
PA8615501A1 (es) Formulaciones farmaceuticas transdermicas
WO1999050239A3 (fr) Nouveaux composes heteroethynylenes et compositions pharmaceutiques et cosmetiques les contenant

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 10 E 13 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.